Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.
Senseonics Holdings (NYSE American: SENS), un'azienda di tecnologia medica specializzata in sistemi di monitoraggio continuo della glicemia impiantabili a lungo termine per pazienti diabetici, ha annunciato la sua partecipazione a due conferenze per investitori in programma a novembre. L'azienda presenterà al Stifel 2024 Healthcare Conference il 19 novembre, offrendo una panoramica aziendale e tenendo incontri individuali, con una presentazione fissata per le 9:10 am ET. Inoltre, la direzione parteciperà al Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum il 21 novembre, conducendo incontri uno a uno. Entrambi gli eventi saranno accessibili tramite webcast attraverso il sito web delle relazioni con gli investitori dell'azienda.
Senseonics Holdings (NYSE American: SENS), una empresa de tecnología médica especializada en sistemas de monitoreo continuo de glucosa implantables a largo plazo para pacientes diabéticos, ha anunciado su participación en dos próximas conferencias para inversores en noviembre. La empresa presentará en la Stifel 2024 Healthcare Conference el 19 de noviembre, ofreciendo una descripción general de la empresa y realizando reuniones individuales, con una presentación programada para las 9:10 a.m. ET. Además, la dirección participará en el Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum el 21 de noviembre, llevando a cabo reuniones uno a uno. Ambos eventos estarán disponibles a través de webcast en el sitio web de relaciones con inversores de la empresa.
센소닉스 홀딩스 (NYSE American: SENS)는 당뇨병 환자를 위한 장기간 이식 가능한 연속 혈당 모니터링 시스템을 전문으로 하는 의료 기술 회사로, 11월에 개최되는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 11월 19일에 열리는 Stifel 2024 Healthcare Conference에서 기업 개요를 발표하고 일대일 회의를 진행하며, 발표는 오전 9시 10분 ET로 예정되어 있습니다. 또한 경영진은 11월 21일에 열리는 Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum에 참석하여 일대일 회의를 진행합니다. 두 행사 모두 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 접속할 수 있습니다.
Senseonics Holdings (NYSE American: SENS), une entreprise de technologie médicale spécialisée dans les systèmes de surveillance continue de la glycémie implantables à long terme pour les patients diabétiques, a annoncé sa participation à deux conférences pour investisseurs prévues en novembre. L'entreprise présentera lors de la Stifel 2024 Healthcare Conference le 19 novembre, offrant un aperçu de l'entreprise et tenant des réunions individuelles, avec une présentation prévue à 9h10 ET. De plus, la direction participera au Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum le 21 novembre, en menant des réunions one-on-one. Les deux événements seront accessibles via webdiffusion sur le site web des relations avec les investisseurs de l'entreprise.
Senseonics Holdings (NYSE American: SENS), ein Medizintechnikunternehmen, das sich auf langfristige, implantierbare Systeme zur kontinuierlichen Glukoseüberwachung für Diabetiker spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im November angekündigt. Das Unternehmen wird am 19. November auf der Stifel 2024 Healthcare Conference präsentieren, eine Unternehmensübersicht geben und Einzelgespräche führen, wobei eine Präsentation um 9:10 Uhr ET vorgesehen ist. Darüber hinaus wird das Management am 21. November am Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum teilnehmen und Einzelgespräche führen. Beide Veranstaltungen werden über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
GERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:
Stifel 2024 Healthcare Conference
Format: Corporate overview and one-on-one meetings
Date: Tuesday, November 19, 2024
Time: 9:10 am ET
Webcast: Click here
Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Format: One-on-one meetings
Date: Thursday, November 21, 2024
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
Investors@senseonics.com
FAQ
When is Senseonics (SENS) presenting at the Stifel 2024 Healthcare Conference?
Which investor conferences is Senseonics (SENS) attending in November 2024?
How can investors access Senseonics (SENS) conference presentations?
What type of meetings will Senseonics (SENS) hold at the Canaccord Genuity Forum?
